GSK Reports Result from Part 2 of the P-III (RUBY) Trial Evaluating Jemperli (dostarlimab) + Zejula (niraparib) to Treat Endometrial Cancer
Shots:
- The P-III (RUBY) study comprises of Part 1, evaluating Jemperli as monotx. and in combination with carboplatin-paclitaxel vs carboplatin-paclitaxel + PBO, followed by PBO and Part 2, assessing Jemperli + carboplatin-paclitaxel followed by Jemperli + Zejula as maintenance therapy vs PBO + carboplatin-paclitaxel followed by PBO for primary advanced/recurrent endometrial cancer
- The results from the part 2 revealed statistically significant and clinically meaningful PFS in the overall patient population and in a subpopulation with MMRp/MSS tumors. OS data is still incomplete and the follow-up continues
- The safety profile was consistent, aligning with the known safety profiles of the individual agents
Ref: GSK | Image: GSK
Related News:- GSK Reports Results of Jemperli in Combination with Chemotherapy in P-III Trial for the Treatment of Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
